Why Titan Pharmaceuticals Shares Are Rising
Shares of Titan Pharmaceuticals saw a handy gain early in Friday’s session following the U.S. Food and Drug Administration (FDA) approval of its partner’s opioid dependence treatment.
Shares of Titan Pharmaceuticals saw a handy gain early in Friday’s session following the U.S. Food and Drug Administration (FDA) approval of its partner’s opioid dependence treatment.
Thermo Fisher Scientific said Friday morning that it has agreed to acquire FEI for approximately $4.2 billion in cash.
These two biotech companies not only have data that could prove to be huge, but the stocks have been absolutely hammered over the past year, offering the best entry points in some time.
Minerva Neurosciences saw its shares make absolutely massive gains on Thursday following the release of positive results from a couple mid-stage clinical trials.
Ionis Pharmaceuticals shares dropped severely after a less-than positive update on its IONIS-TTR Rx program.
Usually the term "hostile takeover" is an exaggeration, but Sanofi's takeover bid for Medivation actually looks pretty hostile, given that it is now trying to oust the entire board.
OvaScience shares dropped early on Thursday after the company announced that it had priced its secondary offering of more than 7 million shares at $7 per share.
Here are four biotech companies that have just either closed fresh financing rounds or issued IPOs that exceeded price expectations.
Many companies are being discussed as Zika virus winners, but the reality is that many of them are so small or have sketchy histories. This is why we are featuring seven notable companies targeting…
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares saw a handy gain on Wednesday following an analyst upgrade from Janney Montgomery Scott.
Cellectar Biosciences watched its shares skyrocket on Wednesday morning following the announcement that it has obtained a patent that covers CLR 1603, a phospholipid ether-paclitaxel.
Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue to stay around.
24/7 Wall St. has collected several big FDA decisions and imminent clinical trial results that should be coming up in the June quarter. We have added some color.
The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.